With the U.S. government poised to approve the use of a drug that could save Canadians money, Canada’s pharmaceutical industry is under scrutiny for the staggering costs associated with the program.
The pharmaceutical industry has been pushing the government to approve a drug called Sovaldi, and has spent more than $12.6 million in taxpayer funds to buy and administer it, according to data released by the federal government this month.
The data, obtained by The Globe and Mail, show that the government spent $12,056,933 on administering Sovaldi and $6,716,788 on marketing the drug.
That’s an increase of more than 30 per cent from the $4.6-million it spent on Sovaldi marketing in 2017.
The government has said it is ready to approve Sovaldi as a prescription drug for a small number of patients, with some provinces already allowing the drug to be used for that purpose.
But critics have said the drug is not yet ready for use in Canada, and that the U!
approval could leave Canadians without access to the drug in their home provinces.
The drug was originally developed in the United States, and was approved for use to treat the severe form of the liver disease Hepatitis C. The U.K. and the U.,S.
have each approved Sovaldi for use as a treatment for that disease, though Canada has not.
The cost of administering Sovalfix, Sovaldi’s main ingredient, has grown steadily in recent years.
In 2018, the government reported it spent $9.3 million on administering the drug, which was $1,567,832 more than it spent in 2017 and $1.8 million more than in 2016.
The government’s annual reports show it spent almost $1 billion on the drug that year.
Since Sovaldi was approved in 2016, it has cost the government $13.3 billion.
The average annual cost for administering Sovafix since it was first approved was $4,569,092.
The drug was initially marketed as a liver drug, but it is now approved for treating cancer and autoimmune diseases.
The Globe and the CBC’s investigative program, In the Public Interest, has documented Sovaldi spending on marketing and marketing costs.
It has found that Sovaldi costs the government an average of $11,800 a year for every drug administered.
The average cost for a Sovaldi prescription has grown to $632,917, with $1 in taxes, according the government.
In 2019, the cost was $2,564,894.
The Liberal government has not responded to questions about the drug and its marketing costs, but has indicated it will not approve Sovaflex for use by Canadians in 2018 or 2020.
In a statement to The Globe, a spokeswoman for Public Safety Minister Ralph Goodale said the government does not comment on private company marketing expenses.
“It is important to note that the drug has been approved in the U of A and is approved for Canadians, with a very limited use for Canadians in that province,” she said.
“The costs associated to administering Sovavid and the cost to administer it in our provinces are shared across the entire country.”
Goodale said it would be premature to comment on the details of the pharmaceutical industry’s marketing costs because of the ongoing regulatory process.
The federal government does, however, release annual financial reports.
In 2017, the department released a report showing that Sovafx sales were $11.9 billion in 2018, up $9 billion from the previous year.
In 2019, Sovaflix sales were up $5.3 and up by more than 8 per cent compared to the previous fiscal year.